Suppr超能文献

特发性肉芽肿性乳腺炎的五年随访

Five-year follow-up of idiopathic granulomatous mastitis.

作者信息

Kaya Mehmet Nur, Tekgöz Emre, Çolak Seda, Kılıç Özlem, Çınar Muhammet, Yılmaz Sedat

机构信息

Rheumatology Department, Gülhane Training and Research Hospital, University of Health Sciences Turkey, Ankara, Turkey.

出版信息

Ir J Med Sci. 2025 Feb;194(1):271-276. doi: 10.1007/s11845-024-03857-5. Epub 2024 Dec 17.

Abstract

BACKGROUND

Idiopathic granulomatous mastitis (IGM) is a benign and rare chronic inflammatory disease of the breast. Although there are various treatment modalities, an ideal treatment algorithm has not been defined.

AIMS

We designed this study to evaluate the clinical status, duration of remission, remission rates, and treatment algorithm in patients with IGM during a 5-year follow-up period after immunosuppressive therapy.

METHODS

This study was planned retrospectively in the rheumatology outpatient clinic including 63 patients with biopsy-proven IGM. Demographic characteristics, clinical findings, treatment options, and drug-free remission periods after treatment were obtained from the patient's records.

RESULTS

The mean age of female patients with IGM was 36.4 ± 6.1 years. Remission was achieved in all patients receiving immunosuppressive treatment and the median remission period was 13.9 months. After 5 years of follow-up, the median remission time without medication was 46.1 months. There was a significant improvement in the laboratory parameters and clinical findings of the patients. The most preferred immunosuppressive agent in all patients was methotrexate, and the second was azathioprine.

CONCLUSION

During the 5-year follow-up period, no recurrence after immunosuppressive therapy was detected in IGM patients. As seen in the treatment management chart, methotrexate provided remission in the majority of patients.

摘要

背景

特发性肉芽肿性乳腺炎(IGM)是一种乳腺的良性罕见慢性炎症性疾病。尽管有多种治疗方式,但尚未确定理想的治疗方案。

目的

我们开展这项研究,以评估免疫抑制治疗后5年随访期内IGM患者的临床状况、缓解持续时间、缓解率及治疗方案。

方法

本研究在风湿科门诊进行回顾性规划,纳入63例经活检证实为IGM的患者。从患者记录中获取人口统计学特征、临床发现、治疗选择及治疗后无药缓解期。

结果

IGM女性患者的平均年龄为36.4±6.1岁。所有接受免疫抑制治疗的患者均实现缓解,中位缓解期为13.9个月。随访5年后,无药中位缓解时间为46.1个月。患者的实验室参数和临床发现有显著改善。所有患者中最常用的免疫抑制剂是甲氨蝶呤,其次是硫唑嘌呤。

结论

在5年随访期内,未检测到IGM患者免疫抑制治疗后复发。如治疗管理图表所示,甲氨蝶呤使大多数患者实现缓解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验